Day: February 5, 2025

GaNFast™ and GeneSiC™ power technologies deliver portability, efficiency, and sustainability for Dell AI notebook computer adapters from 60 W to 360 WNavitas’ GaN & SiC Devices Power Dell’s™ Family of AI NotebooksGaNFast™ and GeneSiC™ power technologies deliver portability, efficiency, and sustainability for Dell AI notebook computer adapters from 60 W to 360 WTORRANCE, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) — Navitas Semiconductor (Nasdaq: NVTS), the industry leader in next-generation GaNFast gallium nitride (GaN) and GeneSiC silicon carbide (SiC) power semiconductors, today announced its adoption of both technologies into Dell’s family of notebook adapters, from 60 W to 360 W. Enabled by over 20 years of SiC technology leadership, GeneSiC leads on performance of SiC MOSFETs with...

SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and Lumea Inc., a leader in digital pathology solutions, have signed an agreement to integrate Myriad’s advanced molecular diagnostic tests — Prolaris® Prostate Cancer Test and MyRisk® Hereditary Cancer Test – into Lumea’s digital pathology platform, BxLink™. This collaboration will streamline the ordering and delivery of molecular tests, enabling healthcare providers to electronically order and track Prolaris and MyRisk tests, with results delivered directly within BxLink’s intuitive platform. By replacing manual processes, the integration will reduce errors and aims to deliver molecular testing results to clinicians in an average of under 10 days after specimen collection. “Clinicians...

88% of customers say they are more likely to return after receiving post-purchase ads that improve the shopping experience through personalized suggestions NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) — Fluent, Inc. (NASDAQ: FLNT), a leading commerce media solutions company, today released the results of a new survey revealing how post-purchase ads enhance the shopping experience, drive product discovery, and encourage repeat purchases. Post-purchase ads, which appear on ecommerce confirmation pages, are designed to keep shoppers engaged with personalized offers after the checkout. With responses from over 1,000 US adults, the survey explores how these ads influence consumer behavior, build loyalty, and create value for both shoppers and retailers. Key survey findings include: Enhancing the Customer Journey57% of shoppers who converted...

PITTSBURGH, Feb. 05, 2025 (GLOBE NEWSWIRE) — Duolingo, Inc. (Nasdaq: DUOL) announced participation at the following investor conferences:Morgan Stanley Technology, Media and Telecom Conference on Monday, March 3rd Citizens JMP Technology Conference on Tuesday, March 4th (Fireside Chat at 2:00 pm PT) KBCM Emerging Technology Summit on Wednesday, March 5th (Fireside Chat at 3:00 pm PT)The conference fireside chats will be available via live audio webcast accessible on the company’s Investor Relations website at investors.duolingo.com/events. About DuolingoDuolingo is the leading mobile learning platform globally. Its flagship app has organically become the world’s most popular way to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. With technology at the...

BETHESDA, Md., Feb. 05, 2025 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, Chief Executive Officer of Gain, will present at two upcoming investor conferences:BIO CEO & Investor Conference on Tuesday, February 11, at 1:15pm ETGene Mack will give a corporate presentation at the Plymouth Room, The New York Marriott Marquis. Registered conference attendees may schedule one-on-one meetings with Gain management via the conference scheduling platform.Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12, at 10:40am ETGene Mack will give a virtual corporate presentation. Interested...

Paperclip’s Encryption Solution to Help EU Finance Sector Comply with New Data Encryption Mandates HACKENSACK, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) — Paperclip, Inc. (OTCMKTS:PCPJ) announces its SAFE technology aligns with new European Union DORA requirements mandating data encryption. The Digital Operational Resilience Act (DORA) went into effect on January 17th, 2025, impacting all European Union (EU) financial services organizations and their Information and Communications Technology (ICT) suppliers. This regulation has far-reaching implications, and not only for Financial Institutions operating in the EU, but for US organizations as well. “We should look at DORA as a foreshadowing of U.S. regulations to come,” said Chad Walter, CRO at Paperclip, Inc. “The demand is increasing for better resiliency due to increased data theft,...

Dr. Thomas Caulfield appointed Executive Chairman, Tim Breen named CEO and Niels Anderskouv named President and COO MALTA, N.Y., Feb. 05, 2025 (GLOBE NEWSWIRE) — GlobalFoundries (Nasdaq: GFS) (GF) today announced, following a rigorous succession planning process, its Board of Directors has appointed Dr. Thomas Caulfield as Executive Chairman and Tim Breen as Chief Executive Officer. Caulfield succeeds Ahmed Yahia who will step down from the Board and his role as Chairman after more than a decade in the position. Breen, who has been with GF since 2018, and is currently Chief Operating Officer (COO), succeeds Caulfield. In addition, Niels Anderskouv, currently GF’s Chief Business Officer, has been appointed GF’s President and COO. With a strong foundation in place, this leadership transition positions GF to accelerate its next phase...

BASKING RIDGE, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, PhD, President and Chief Executive Officer of Lisata, will present a corporate overview at the 2025 BIO CEO & Investor Conference taking place February 10-11, 2025 at the New York Marriott Marquis in New York City. Dr. Mazzo’s presentation is scheduled for Monday, February 10th at 2:00 p.m. Eastern Time. For more information about the conference and how to register, please visit https://bcic.bio.org/registration. About Lisata Therapeutics Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery,...

SCHAUMBURG, IL, Feb. 05, 2025 (GLOBE NEWSWIRE) — Giftify, Inc. (NASDAQ: GIFT) (the “Company”), the owner and operator of leading digital platforms, CardCash.com and Restaurant.com, with a focus on incentives and rewards in retail, dining & entertainment experiences, today announced the cancellation of its equity line of credit (ELOC). On December 16, 2024, the Company entered into a common stock purchase agreement (the “SPA”) with an institutional investor. Pursuant to the SPA, the Company had the right, but not the obligation, to sell to the Investor, up to $10,000,000 of newly issued shares of the Company’s common stock, subject to certain limitations and conditions. The Company has exercised its right to terminate the SPA effective February 4, 2025 by mutual agreement of the parties. About Giftify, Inc. Giftify, Inc. is...

PHOENIX, Feb. 05, 2025 (GLOBE NEWSWIRE) — Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical”), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced an expanded agreement with Greenstone Biosciences Inc. (“Greenstone”) to leverage Artificial Intelligence (AI) in further developing its human induced pluripotent stem cell (iPSC) platform for diabetes treatment. This strategic collaboration extends the progress made on Creative Medical’s proprietary hypoimmune iPSC technology, including its iPSC-derived pancreatic islet cells. These innovative cell lines, developed from Good Manufacturing Practice (GMP) grade human perinatal cells, are currently being used in clinical trials. By integrating AI-driven drug discovery, the partnership aims to identify small molecules...